Your Patients Need Rifaximin — But Many Can't Afford It Without Help

Rifaximin (Xifaxan) is a clinically effective, gut-targeted antibiotic with clear evidence supporting its use in hepatic encephalopathy, IBS-D, and travelers' diarrhea. But with a cash price of $1,800 to $2,400 per month and no generic available until at least 2029, cost is the single biggest barrier to adherence for many of your patients.

As a prescriber, you're often the first person patients turn to when they see the price at the pharmacy counter. This guide outlines the savings programs, assistance options, and conversation strategies that can help your patients access the Rifaximin they need — without financial devastation.

For additional provider resources, visit Medfinder for Providers.

What Your Patients Are Actually Paying

Understanding the real-world cost landscape helps frame the conversation:

• Cash price (no insurance): $1,800–$2,400 for 60 tablets of 550 mg (30-day supply for hepatic encephalopathy at 550 mg BID).
• Commercially insured patients: Copays range widely — from $50 to $500+ per fill depending on formulary tier and plan design. Rifaximin typically lands on Tier 3 or specialty tier.
• Medicare Part D: Patients may face significant cost-sharing in the coverage gap (donut hole). Manufacturer copay cards are generally not usable with government insurance.
• Uninsured/underinsured: Full cash price unless a patient assistance program (PAP) is secured.

Many patients don't fill the prescription at all when they learn the price. Others fill the first month and then discontinue — a particular concern for hepatic encephalopathy patients on long-term maintenance therapy where adherence directly affects hospitalization rates.

Manufacturer Savings Programs

Xifaxan Savings Card (Bausch Health / Salix Pharmaceuticals)

The primary first-line savings tool for commercially insured patients:

• Eligibility: Commercially insured patients with a valid Rifaximin prescription. Not available for patients on Medicare, Medicaid, Tricare, or other government-funded programs.
• Benefit: Eligible patients may pay as little as $0–$75 per prescription.
• Enrollment: Patients can enroll at xifaxan.com or by calling the number on the Xifaxan website. Cards can often be activated at the point of care.
• Tip for your practice: Keep printed savings card information in your clinic. Hand it to the patient at the time of prescribing — before they reach the pharmacy. This prevents sticker shock and reduces prescription abandonment.

Bausch Health Patient Assistance Program (PAP)

For uninsured and underinsured patients who cannot afford Rifaximin at any price:

• Eligibility: Typically requires proof of income below a specified threshold (often 300–400% of the federal poverty level), no commercial insurance, and U.S. residency.
• Benefit: Free medication for qualifying patients.
• Application: Requires a provider signature. Forms are available through the Bausch Health website or through intermediaries like NeedyMeds (needymeds.org) and RxAssist (rxassist.org).
• Processing time: Typically 2–4 weeks. Plan ahead — do not wait until the patient's current supply runs out.

Coupon Cards and Discount Programs

For patients who don't qualify for manufacturer programs or need a bridge while PAP applications are processed:

GoodRx, SingleCare, and Other Coupon Platforms

• These platforms aggregate pharmacy pricing and offer free coupons that can reduce the cash price at checkout.
• For a brand-only drug like Rifaximin, discounts may be modest (5–15% off cash price), but every dollar matters to patients paying out of pocket.
• Coupons are generally accepted at major chain pharmacies (CVS, Walgreens, Walmart, Rite Aid).
• Patients can compare prices at goodrx.com, singlecare.com, or through your pharmacy's app.

Specialty Pharmacy Discount Programs

Some specialty pharmacies negotiate directly with manufacturers or PBMs and can offer better pricing on high-cost brand drugs. If your patient's retail pharmacy quotes a high price, a specialty pharmacy referral may help.

For a comprehensive list of savings options, direct patients to: How to Save Money on Rifaximin.

Generic Alternatives — Current Status

Providers frequently ask about generic Rifaximin. Here's the current landscape:

• No generic is currently available in the United States.
• A patent settlement between Bausch Health and Teva delays authorized generic entry until 2029.
• Until then, Xifaxan remains the only FDA-approved Rifaximin product on the U.S. market.

Therapeutic Alternatives to Consider

When cost is truly prohibitive and the patient cannot access any savings program, clinical alternatives may need to be discussed depending on the indication:

• Hepatic encephalopathy: Lactulose remains the first-line, lower-cost therapy. While evidence supports Rifaximin as add-on therapy for reducing HE recurrence, some patients may need to rely on Lactulose alone if Rifaximin is inaccessible.
• IBS-D: Alosetron (for severe cases in women), Eluxadoline, dietary modification (low-FODMAP diet), and antispasmodics may be considered.
• Travelers' diarrhea: Fluoroquinolones (Ciprofloxacin) or Azithromycin are lower-cost alternatives, though with different resistance and side effect profiles.

For a detailed look at alternatives, see: Alternatives to Rifaximin.

Having the Cost Conversation With Patients

Many patients are embarrassed to bring up medication costs. As a provider, proactively addressing affordability can improve adherence and outcomes:

Strategies That Work

• Mention cost early: "I'm prescribing Rifaximin. It's an expensive medication, so let me give you some information about savings programs before you leave today."
• Normalize the struggle: "A lot of my patients have been surprised by the cost of this drug. You're not alone, and there are options."
• Involve your staff: Train medical assistants or care coordinators to hand out savings card information and assist with PAP applications. This takes the burden off the provider and improves follow-through.
• Document prior authorization proactively: Rifaximin frequently requires PA. Initiating the process at the time of prescribing — rather than waiting for the pharmacy to reject the claim — saves days and reduces patient frustration.
• Follow up on fills: If your EHR tracks prescription fill status, check whether the patient actually filled the Rifaximin. A prescription that's never filled helps no one.

For Medicare and Government-Insured Patients

Since manufacturer copay cards aren't available for these patients, explore:

• State pharmaceutical assistance programs (SPAPs)
• Extra Help / Low-Income Subsidy (LIS) for Medicare Part D
• Foundation-based copay assistance (Patient Access Network Foundation, HealthWell Foundation) — availability for Rifaximin specifically varies by year and funding
• Direct PAP application through Bausch Health

Helping Patients Find Rifaximin in Stock

Even after resolving cost barriers, some patients struggle to find Rifaximin at their local pharmacy. As a prescriber, you can help by:

• Recommending Medfinder to check real-time pharmacy availability
• E-prescribing to specialty pharmacies that are more likely to stock high-cost brand medications
• Suggesting mail-order pharmacy options through the patient's PBM

For more on availability challenges, see: Rifaximin Shortage: What Providers Need to Know.

Final Thoughts

Rifaximin is a valuable medication, but its cost creates a real barrier for many patients. By proactively connecting patients with the Xifaxan Savings Card, Bausch Health's PAP, and coupon platforms — and by initiating prior authorization at the point of prescribing — you can significantly improve the odds that your patients actually fill and stay on their Rifaximin prescription.

The cost conversation doesn't have to be long or complicated. A 30-second mention and a handout can make the difference between a patient who fills their prescription and one who doesn't.

For more provider resources and tools, visit Medfinder for Providers.